2024
Progesterone receptor status predicts aggressiveness of human endometriotic lesions in murine avatars
Flores V, Sahin C, Taylor H. Progesterone receptor status predicts aggressiveness of human endometriotic lesions in murine avatars. F&S Science 2024, 6: 65-72. PMID: 39393571, DOI: 10.1016/j.xfss.2024.10.004.Peer-Reviewed Original ResearchProgestin-based therapyAggressive forms of endometriosisPR lesionsProgesterone receptorGnRH antagonistMedroxyprogesterone acetatePR statusEndometriotic lesionsAggressive formResponse to MPAResponse to medical therapyPost-treatment sizeProgesterone receptor statusHuman endometriotic lesionsResponse to progestinsChronic gynecological diseaseDaily subcutaneous injectionsReproductive-age womenMouse xenograft modelResponse to medicationEndometrioma lesionsReceptor statusHormone suppressionPR expressionClinical responseUterine fibroid–related infertility: mechanisms and management
Donnez J, Taylor H, Marcellin L, Dolmans M. Uterine fibroid–related infertility: mechanisms and management. Fertility And Sterility 2024, 122: 31-39. PMID: 38453041, DOI: 10.1016/j.fertnstert.2024.02.049.Peer-Reviewed Original ResearchUterine artery embolizationUterine fibroidsAssociation of fibroidsAdd-back therapyHeavy menstrual bleedingBaseline to weekOral GnRH antagonistPresence of fibroidsNon-surgical approachFocused ultrasoundFibroid volumeMyoma volumeArtery embolizationMenstrual bleedingCurrent management strategiesGnRH antagonistEchographic guidanceSurgical interventionFibroidsInfertilityMedical treatmentUterineWomenOptimal dosageSource of controversy
2023
Clinical applications of gonadotropin-releasing hormone analogues: a broad impact on reproductive medicine
Saleh F, Taylor H. Clinical applications of gonadotropin-releasing hormone analogues: a broad impact on reproductive medicine. F&S Reports 2023, 4: 83-87. PMID: 37223759, PMCID: PMC10201293, DOI: 10.1016/j.xfre.2023.01.008.Peer-Reviewed Original ResearchHormone analogueGonadotropin-releasing hormone analogueOral GnRH antagonistCommon gynecologic conditionOvarian hormone productionClinical applicationGnRH antagonistPituitary responseGnRH activityGnRH analoguesGynecologic conditionsTreatment optionsGonadal axisReproductive axisRapid onsetGynecologic practiceHormone productionReproductive medicineReproductive technologiesDiverse clinical applicationsGonadotropinEndometriosisFibroidsGnRHAntagonist
2022
O-163 Pathophysiology – what’s new
Taylor H. O-163 Pathophysiology – what’s new. Human Reproduction 2022, 37: deac105.073. DOI: 10.1093/humrep/deac105.073.Peer-Reviewed Original ResearchSystemic diseaseGynecological diseasesOral gonadotropin-releasing hormone antagonistClinical diagnosisLow-dose oral contraceptivesGonadotropin-releasing hormone antagonistEndometrial-like tissueFirst-line medicationAccurate clinical diagnosisFemale reproductive tractOral contraceptivesPrompt treatmentSystemic inflammationGnRH antagonistPain sensitizationProgesterone resistanceSymptomatic womenClinical presentationRetrograde menstruationEndometriosis careHormone antagonistReproductive ageEffective therapyTherapeutic alternativeMood disordersPre-IVF treatment with a GnRH antagonist in women with endometriosis (PREGNANT): study protocol for a prospective, double-blind, placebo-controlled trial
Taylor H, Li HJ, Carson S, Flores V, Pal L, Robbins J, Santoro NF, Segars JH, Seifer D, Huang H, Young S, Zhang H. Pre-IVF treatment with a GnRH antagonist in women with endometriosis (PREGNANT): study protocol for a prospective, double-blind, placebo-controlled trial. BMJ Open 2022, 12: e052043. PMID: 35715184, PMCID: PMC9207753, DOI: 10.1136/bmjopen-2021-052043.Peer-Reviewed Original ResearchConceptsEndometriosis-associated infertilityPlacebo-controlled trialGnRH antagonistFertility treatmentOral GnRH antagonistEndometriosis-related infertilityFertilization-embryo transferLive birth rateUse of gonadotropinsEtiology of infertilityInstitutional review boardAntagonist pretreatmentCommon complicationObstetrical outcomesPeer-reviewed journalsSecondary outcomesIVF treatmentPrimary outcomeHormone agonistImplantation ratePregnancy rateLive birthsEndometriosisLocal protocolsOocyte numberQuality of Life Improvements in Women with Uterine Fibroids: Results of Two Phase 3 Trials with Linzagolix [A107]
Al-Hendy A, Bradley L, Taylor H, Catherino W, Humberstone A, Garner E. Quality of Life Improvements in Women with Uterine Fibroids: Results of Two Phase 3 Trials with Linzagolix [A107]. Obstetrics And Gynecology 2022, 139: 31s-31s. DOI: 10.1097/01.aog.0000826748.26150.66.Peer-Reviewed Original ResearchPhase 3 trialUterine fibroidsPlacebo-controlled phase 3 trialTreatment of UFsFibroid-related symptomsHealth-related qualifyOral GnRH antagonistHealth-related qualityEnd of treatmentLong-term impairmentSubstantial beneficial effectPlacebo groupGnRH antagonistLife QuestionnaireSexual functionWeek 64Mean changeFrequent causeTreatment terminationEstradiol suppressionTreatment groupsLinzagolixPooled populationBeneficial effectsTotal scoreIncidence of Alopecia in Treatment of Women With Uterine Fibroids: Results of Two Phase 3 Trials of Linzagolix [A104]
Al-Hendy A, Taylor H, Catherino W, Stewart E, Bestel E, Garner E. Incidence of Alopecia in Treatment of Women With Uterine Fibroids: Results of Two Phase 3 Trials of Linzagolix [A104]. Obstetrics And Gynecology 2022, 139: 30s-30s. DOI: 10.1097/01.aog.0000826736.08037.1b.Peer-Reviewed Original ResearchPhase 3 trialUterine fibroidsGnRH antagonistHair lossPlacebo-controlled phase 3 trialUterine fibroid-related symptomsFibroid-related symptomsIncidence of alopeciaOral GnRH antagonistPooled safety analysisTreatment of womenConcomitant therapyTreatment discontinuationStudy drugWeek 52Mild alopeciaWeek 24Benign disorderSimilar incidenceLinzagolixSuppression dosesAlopeciaFibroidsTrialsTreatment
2021
Eliminating Hormones With Orally Active Gonadotropin-releasing Hormone Antagonists
Kotlyar AM, Pal L, Taylor HS. Eliminating Hormones With Orally Active Gonadotropin-releasing Hormone Antagonists. Clinical Obstetrics & Gynecology 2021, 64: 837-849. PMID: 34668887, DOI: 10.1097/grf.0000000000000664.Peer-Reviewed Original ResearchConceptsGnRH antagonistSmall molecule GnRH antagonistsClinical practiceSex steroid suppressionHormone-dependent diseasesSmall molecule antagonistsGnRH agonistSteroid suppressionGnRH analoguesGonadotropin productionHormone antagonistAntagonistHormone analogueGonadotropinActive gonadotropinsReproductive technologiesAgonistsDiseaseHormoneWillingness of Women with Endometriosis Planning to Undergo IVF to Participate in a Randomized Clinical Trial and the Effects of the COVID-19 Pandemic on Potential Participation
Pretzel S, Kuhn K, Pal L, Polotsky A, Taylor HS, Zhang H, Robins J, Young SL, Santoro N. Willingness of Women with Endometriosis Planning to Undergo IVF to Participate in a Randomized Clinical Trial and the Effects of the COVID-19 Pandemic on Potential Participation. Reproductive Sciences 2021, 29: 620-626. PMID: 34363198, PMCID: PMC8345905, DOI: 10.1007/s43032-021-00705-0.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultChoice BehaviorCOVID-19Double-Blind MethodElectronic Health RecordsEndometriosisFemaleFertility Agents, FemaleFertilization in VitroGonadotropin-Releasing HormoneHealth Knowledge, Attitudes, PracticeHormone AntagonistsHumansInfertility, FemaleLive BirthPatient SelectionPregnancyPregnancy RateResearch SubjectsTreatment OutcomeUnited StatesYoung AdultConceptsGnRH antagonistClinical trialsEndometriosis diagnosisSuperior live birth ratesCOVID-19Relevant ICD-10 codesOral GnRH antagonistLive birth rateAge-eligible womenICD-10 codesElectronic medical recordsSurvey of womenIVF cyclesEligible womenWillingness of womenInfertility diagnosisMedical recordsFertility treatmentIVFWomenDiagnosisTrialsBirth rateTreatmentCOVID-19 pandemicEndometriosis is a chronic systemic disease: clinical challenges and novel innovations
Taylor HS, Kotlyar AM, Flores VA. Endometriosis is a chronic systemic disease: clinical challenges and novel innovations. The Lancet 2021, 397: 839-852. PMID: 33640070, DOI: 10.1016/s0140-6736(21)00389-5.Peer-Reviewed Original ResearchConceptsSystemic diseaseGynaecological diseaseOral gonadotropin-releasing hormone antagonistClinical diagnosisLow-dose oral contraceptivesGonadotropin-releasing hormone antagonistEndometrial-like tissueChronic systemic diseaseFirst-line medicationAccurate clinical diagnosisFemale reproductive tractPain sensitisationOral contraceptivesPrompt treatmentSystemic inflammationGnRH antagonistProgesterone resistanceSymptomatic womenClinical presentationRetrograde menstruationEndometriosis careHormone antagonistReproductive ageEffective therapyTherapeutic alternative
2018
Long-Term Safety and Efficacy of Elagolix Treatment in Women With Endometriosis-Associated Pain [11OP]
Surrey E, Taylor H, Duan W, Peloso P, Schwefel B, Chwalisz K. Long-Term Safety and Efficacy of Elagolix Treatment in Women With Endometriosis-Associated Pain [11OP]. Obstetrics And Gynecology 2018, 131: 4s. DOI: 10.1097/01.aog.0000533299.54528.7c.Peer-Reviewed Original ResearchNon-menstrual pelvic painEndometriosis-associated painBone mineral densityAdverse eventsPivotal studiesElagolix treatmentLumbar spine BMD Z-scoreExtension studyNon-peptide GnRH antagonistsSevere endometriosis-associated painSpine BMD Z-scoreEfficacy of elagolixCommon adverse eventsPhase 3 studyBMD Z-scoresNew safety concernsLong-term safetyDose-dependent decreaseDyspareunia scoresEndometrial thicknessPelvic painHot flushesGnRH antagonistDose groupMineral density
2011
Testosterone lowers microvascular ET‐B receptor responsiveness in women with PCOS
Wenner M, Taylor H, Stachenfeld N. Testosterone lowers microvascular ET‐B receptor responsiveness in women with PCOS. The FASEB Journal 2011, 25: lb559-lb559. DOI: 10.1096/fasebj.25.1_supplement.lb559.Peer-Reviewed Original ResearchPolycystic ovary syndromeHeat-induced vasodilationT administrationCutaneous vascular conductance responsesET-1 plasma concentrationsET-B receptor antagonistImpaired microvascular functionET-B receptorsVascular conductance responsesEndogenous sex hormonesLaser Doppler flowmetryPCOS showOvary syndromeGnRH antagonistMicrovascular functionVascular dysfunctionReceptor antagonistReceptor responsivenessMicrodialysis infusionSex hormonesPlasma concentrationsDoppler flowmetryReceptor sensitivityT exposureTestosterone exposureProgesterone enhances adrenergic control of skin blood flow in women with high but not low orthostatic tolerance
Wenner MM, Taylor HS, Stachenfeld NS. Progesterone enhances adrenergic control of skin blood flow in women with high but not low orthostatic tolerance. The Journal Of Physiology 2011, 589: 975-986. PMID: 21173076, PMCID: PMC3060374, DOI: 10.1113/jphysiol.2010.194563.Peer-Reviewed Original ResearchConceptsLow orthostatic toleranceHigh orthostatic toleranceOrthostatic toleranceAdrenergic responseAdrenergic responsivenessNitric oxide synthase inhibitor NG-monomethylEndogenous sex hormone productionSynthase inhibitor NG-monomethylSkin blood flow responseBlood flow responseInhibitor NG-monomethylSex hormone productionFemale sex hormonesLower body negative pressure testSkin blood flowGnRH antagonistProgesterone administrationOrthostatic intoleranceNG-monomethylPeripheral αMicrodialysis infusionSex hormonesCyclooxygenase pathwayHT womenAdrenergic control
2010
Peripheral microvascular responses to norepinephrine in women with orthostatic intolerance
Wenner M, Taylor H, Stachenfeld N. Peripheral microvascular responses to norepinephrine in women with orthostatic intolerance. The FASEB Journal 2010, 24: 991.17-991.17. DOI: 10.1096/fasebj.24.1_supplement.991.17.Peer-Reviewed Original ResearchCumulative stress indexVasoconstrictor responsesAdrenergic responseMaximal lower body negative pressureLower body negative pressurePeripheral microvascular responseEffects of estradiolBody negative pressureFemale sex hormonesSkin blood flowEndogenous E2GnRH antagonistNE infusionDaily administrationMicrovascular responsesCutaneous microvasculatureOrthostatic intoleranceOrthostatic toleranceSex hormonesBlood flowSkin microvasculatureAdrenergic stimulationDay 4Hormone treatmentDay 13
2008
GnRH antagonists may affect endometrial receptivity
Rackow BW, Kliman HJ, Taylor HS. GnRH antagonists may affect endometrial receptivity. Fertility And Sterility 2008, 89: 1234-1239. PMID: 18410932, PMCID: PMC2699407, DOI: 10.1016/j.fertnstert.2007.04.060.Peer-Reviewed Original ResearchConceptsGnRH antagonistEndometrial stromal cellsEndometrial receptivityHOXA10 protein expressionHOXA10 expressionGnRH agonistControl subjectsProspective case-control studyStromal cellsEndometrial HOXA10 expressionPipelle endometrial biopsyProtein expressionSpontaneous LH surgeCase-control studyAcademic medical centerNatural cycleOvarian hyperstimulationRecombinant FSHEndometrial biopsyHCG administrationUntreated cyclesEndometrial glandsLH surgeMedical CenterMAIN OUTCOME
2007
Exogenous oestradiol and progesterone administration does not cause oedema in healthy young women
Stachenfeld NS, Taylor HS. Exogenous oestradiol and progesterone administration does not cause oedema in healthy young women. Clinical Endocrinology 2007, 66: 410-418. PMID: 17302877, DOI: 10.1111/j.1365-2265.2007.02748.x.Peer-Reviewed Original ResearchConceptsExtracellular fluid volumeTranscapillary albumin escape rateGonadotropin-releasing hormone antagonistPmol/Plasma renin activitySerum aldosterone concentrationHealthy young womenAlbumin escape rateRenin activityAldosterone concentrationGnRH antagonistHealthy womenProgesterone administrationExogenous oestradiolIntravascular volumeHormone antagonistProgesterone increaseDay 2Day 5Hormone treatmentOestradiolDay 13Extravascular componentOncotic pressureYoung women
2005
Progesterone increases plasma volume independent of estradiol
Stachenfeld NS, Taylor HS. Progesterone increases plasma volume independent of estradiol. Journal Of Applied Physiology 2005, 98: 1991-1997. PMID: 15718411, DOI: 10.1152/japplphysiol.00031.2005.Peer-Reviewed Original ResearchConceptsTranscapillary escape ratePlasma concentrationsPlasma volumeGnRH antagonistECF volumeAdequate plasma volumeAldosterone system stimulationPlasma renin activityGonadotropin-releasing hormoneExtracellular fluid volumeRenin activitySerum aldosteroneAng IIBlood pressureEstrogen administrationSystem stimulationDay 2Day 5Pg/Day 13Fluid regulationPV expansionFluid volumeIndependent effectsProgesterone
2004
Responses to a Saline Load in Gonadotropin-Releasing Hormone Antagonist-Pretreated Premenopausal Women Receiving Progesterone or Estradiol-Progesterone Therapy
Stachenfeld NS, Keefe DL, Taylor HS. Responses to a Saline Load in Gonadotropin-Releasing Hormone Antagonist-Pretreated Premenopausal Women Receiving Progesterone or Estradiol-Progesterone Therapy. The Journal Of Clinical Endocrinology & Metabolism 2004, 90: 386-394. PMID: 15486051, DOI: 10.1210/jc.2004-0941.Peer-Reviewed Original ResearchConceptsSodium regulationOvarian hyperstimulation syndromeEffects of estradiolMin of restImportant clinical implicationsHyperstimulation syndromeSodium excretionGnRH antagonistRenal diseaseSodium loadIsotonic salineClinical implicationsSyndromeReproductive syndromeSubjectsPreeclampsiaGnRHGroupEstradiolProgesteroneAntagonistExcretionDiseaseAdministrationSaline
2003
Effects of estrogen and progesterone administration on extracellular fluid
Stachenfeld NS, Taylor HS. Effects of estrogen and progesterone administration on extracellular fluid. Journal Of Applied Physiology 2003, 96: 1011-1018. PMID: 14660504, DOI: 10.1152/japplphysiol.01032.2003.Peer-Reviewed Original ResearchConceptsGnRH antagonist administrationExtracellular fluid volumeGnRH antagonistEffects of estrogenAntagonist administrationPlasma volumeTranscapillary escape rateGonadotropin-releasing hormoneExtracellular fluidHealthy womenProgesterone administrationECFV expansionGanirelix acetateEndogenous estrogensStrong negative predictorDay 2Day 5Pg/AntagonistEstrogenDay 12Plasma compartmentCapillary endotheliumAdministrationProgesteroneEndometrial HOXA10 expression after controlled ovarian hyperstimulation with recombinant follicle-stimulating hormone
Taylor HS, Daftary GS, Selam B. Endometrial HOXA10 expression after controlled ovarian hyperstimulation with recombinant follicle-stimulating hormone. Fertility And Sterility 2003, 80: 839-843. PMID: 14505762, DOI: 10.1016/s0015-0282(03)00985-3.Peer-Reviewed Original ResearchMeSH KeywordsAdultEmbryo ImplantationEndometriumEstradiolFemaleFertility Agents, FemaleFollicle Stimulating HormoneGonadotropin-Releasing HormoneHomeobox A10 ProteinsHomeodomain ProteinsHormone AntagonistsHumansLeuprolideOvulation InductionProspective StudiesRecombinant ProteinsReverse Transcriptase Polymerase Chain ReactionRNATumor Cells, CulturedConceptsEndometrial HOXA10 expressionOvarian hyperstimulationRecombinant FSHReverse transcriptase-polymerase chain reactionGnRH agonistGnRH antagonistHOXA10 expressionFertile controlsRecombinant follicle-stimulating hormoneCycle day 21Pipelle endometrial biopsyFollicle-stimulating hormoneQuantitative reverse transcriptase-polymerase chain reactionTranscriptase-polymerase chain reactionAcademic medical centerDose-dependent mannerEndometrial biopsyEndometrial receptivityProspective studyIshikawa cellsMedical CenterHyperstimulationMAIN OUTCOMEFSHDay 21
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply